BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 34921025)

  • 21. MERTK Promotes Resistance to Irreversible EGFR Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancers Expressing Wild-type
    Yan D; Parker RE; Wang X; Frye SV; Earp HS; DeRyckere D; Graham DK
    Clin Cancer Res; 2018 Dec; 24(24):6523-6535. PubMed ID: 30194074
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer.
    Zhang K; Yuan Q
    J Cancer Res Ther; 2016 Dec; 12(Supplement):C131-C137. PubMed ID: 28230005
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lymecycline reverses acquired EGFR-TKI resistance in non-small-cell lung cancer by targeting GRB2.
    Chen Y; Wu J; Yan H; Cheng Y; Wang Y; Yang Y; Deng M; Che X; Hou K; Qu X; Zou D; Liu Y; Zhang Y; Hu X
    Pharmacol Res; 2020 Sep; 159():105007. PubMed ID: 32561477
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of β-Catenin enhances the anticancer effect of irreversible EGFR-TKI in EGFR-mutated non-small-cell lung cancer with a T790M mutation.
    Togashi Y; Hayashi H; Terashima M; de Velasco MA; Sakai K; Fujita Y; Tomida S; Nakagawa K; Nishio K
    J Thorac Oncol; 2015 Jan; 10(1):93-101. PubMed ID: 25384171
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting CD73 to Overcomes Resistance to First-Generation EGFR Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer.
    Kim M; Kim S; Yim J; Keam B; Kim TM; Jeon YK; Kim DW; Heo DS
    Cancer Res Treat; 2023 Oct; 55(4):1134-1143. PubMed ID: 37218137
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preclinical Study of a Biparatopic METxMET Antibody-Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC.
    Oh SY; Lee YW; Lee EJ; Kim JH; Park Y; Heo SG; Yu MR; Hong MH; DaSilva J; Daly C; Cho BC; Lim SM; Yun MR
    Clin Cancer Res; 2023 Jan; 29(1):221-232. PubMed ID: 36269795
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mutations in the MET tyrosine kinase domain and resistance to tyrosine kinase inhibitors in non-small-cell lung cancer.
    Yao Y; Yang H; Zhu B; Wang S; Pang J; Wu X; Xu Y; Zhang J; Zhang J; Ou Q; Tian H; Zhao Z
    Respir Res; 2023 Jan; 24(1):28. PubMed ID: 36698189
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeted sequencing identifies genetic alterations that confer primary resistance to EGFR tyrosine kinase inhibitor (Korean Lung Cancer Consortium).
    Lim SM; Kim HR; Cho EK; Min YJ; Ahn JS; Ahn MJ; Park K; Cho BC; Lee JH; Jeong HC; Kim EK; Kim JH
    Oncotarget; 2016 Jun; 7(24):36311-36320. PubMed ID: 27121209
    [TBL] [Abstract][Full Text] [Related]  

  • 29. EGFR-mutant NSCLC may remodel TME from non-inflamed to inflamed through acquiring resistance to EGFR-TKI treatment.
    Chen Q; Xia L; Wang J; Zhu S; Wang J; Li X; Yu Y; Li Z; Wang Y; Zhu G; Lu S
    Lung Cancer; 2024 Jun; 192():107815. PubMed ID: 38754276
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Circulating Proteoglycan Endocan Mediates EGFR-Driven Progression of Non-Small Cell Lung Cancer.
    Yang YC; Pan KF; Lee WJ; Chang JH; Tan P; Gu CC; Chang WM; Yang SF; Hsiao M; Hua KT; Chien MH
    Cancer Res; 2020 Aug; 80(16):3292-3304. PubMed ID: 32561533
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting the IL-1β/EHD1/TUBB3 axis overcomes resistance to EGFR-TKI in NSCLC.
    Huang J; Lan X; Wang T; Lu H; Cao M; Yan S; Cui Y; Jia D; Cai L; Xing Y
    Oncogene; 2020 Feb; 39(8):1739-1755. PubMed ID: 31740781
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells.
    Presutti D; Santini S; Cardinali B; Papoff G; Lalli C; Samperna S; Fustaino V; Giannini G; Ruberti G
    PLoS One; 2015; 10(11):e0143333. PubMed ID: 26580964
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting Acquired and Intrinsic Resistance Mechanisms in Epidermal Growth Factor Receptor Mutant Non-Small-Cell Lung Cancer.
    Shah MP; Neal JW
    Drugs; 2022 Apr; 82(6):649-662. PubMed ID: 35412115
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The clinical significance and function of EGFR mutation in TKI treatments of NSCLC patients.
    Ding H; Chen Y; Zhao Y; Zhu L; Huang H; Liu C; Zhang F; Zhang C; Jin C
    Cancer Biomark; 2022; 35(1):119-125. PubMed ID: 35912729
    [TBL] [Abstract][Full Text] [Related]  

  • 35. IRS4 promotes the progression of non-small cell lung cancer and confers resistance to EGFR-TKI through the activation of PI3K/Akt and Ras-MAPK pathways.
    Hao P; Huang Y; Peng J; Yu J; Guo X; Bao F; Dian Z; An S; Xu TR
    Exp Cell Res; 2021 Jun; 403(2):112615. PubMed ID: 33894221
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Heterogeneous resistance mechanisms in an EGFR exon 19-mutated non-small cell lung cancer patient treated with erlotinib: Persistent FGFR3-mutation, localized transformation to EGFR-mutated SCLC, and acquired T790M EGFR-mutation.
    Santoni-Rugiu E; Grauslund M; Melchior LC; Costa JC; Sørensen JB; Urbanska EM
    Lung Cancer; 2017 Nov; 113():14-17. PubMed ID: 29110841
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dual targeting of MEK and PI3K effectively controls the proliferation of human EGFR-TKI resistant non-small cell lung carcinoma cell lines with different genetic backgrounds.
    Qu GP; Shi M; Wang D; Wu JH; Wang P; Gong ML; Zhang ZJ
    BMC Pulm Med; 2021 Jul; 21(1):208. PubMed ID: 34210314
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New Strategies and Novel Combinations in EGFR TKI-Resistant Non-small Cell Lung Cancer.
    Girard N
    Curr Treat Options Oncol; 2022 Nov; 23(11):1626-1644. PubMed ID: 36242712
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non-small cell lung cancer.
    Ali A; Levantini E; Teo JT; Goggi J; Clohessy JG; Wu CS; Chen L; Yang H; Krishnan I; Kocher O; Zhang J; Soo RA; Bhakoo K; Chin TM; Tenen DG
    EMBO Mol Med; 2018 Mar; 10(3):. PubMed ID: 29449326
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Epidermal growth factor receptor cooperates with Src family kinases in acquired resistance to cetuximab.
    Wheeler DL; Iida M; Kruser TJ; Nechrebecki MM; Dunn EF; Armstrong EA; Huang S; Harari PM
    Cancer Biol Ther; 2009 Apr; 8(8):696-703. PubMed ID: 19276677
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.